PD membrane: Biological responses to different PD fluids

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 48-53

  Jörres, Achim ^a   Witowski, Janusz ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS FLUID; GLUCOSE;

HUMAN; MEMBRANE; METABOLISM; PERITONEAL DIALYSIS; PERITONEUM; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; DIALYSIS SOLUTIONS; GLUCOSE; HUMANS; MEMBRANES; PERITONEAL DIALYSIS; PERITONEUM;

EID: 33745261274     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093501     Document Type: Review

References (36)

1. Yung S, Davies M: Response of the human peritoneal mesothelial cell to injury: an in vitro model of peritoneal wound healing. Kidney Int 1998;54:2160-2169.
2. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al: Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003;64:1854-1866.
3. Rubin J, Herrera GA, Collins D: An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991;18:97-102.
4. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479.
5. Kakuta T, Tanaka R, Satoh Y, Izuhara Y, Inagi R, Nangaku M, et al: Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 2005;68:1326-1336.
6. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. JAm Soc Nephrol 2001;12:1046-1051.
7. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS: Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004;66:1257-1265.
8. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999;14:1541-1549.
9. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
10. Lai KN, Leung JC, Chan LY, Li FF, Tang SC, Lam MF, et al: Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004;138:466-475.
11. Nevado J, Peiro C, Vallejo S, El Assar M, Lafuente N, Matesanz N, et al: Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells. Br J Pharmacol 2005;146:268-279.
12. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al: Peritoneal dialysis and epithelial-to- mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413.
13. Aroeira LS, Aguilera A, Selgas R, Ramirez-Huesca M, Perez-Lozano ML, Cirugeda A, et al: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005;46:938-948.
14. Jörres A, Gahl GM, Frei U: In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. Perit Dial Int 1995;15:S41-S45.
15. Jörres A, Gahl GM, Frei U: Peritoneal dialysis fluid biocompatibility: does it really matter? Kidney Int Suppl 1994;48:S79-S86.
16. Lage C, Pischetsrieder M, Aufricht C, Jörres A, Schilling H, Passlick-Deetjen J: First in vitro and in vivo experiences with stay-safe balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000;20(suppl 5):S28-S32.
17. Jörres A, Williams JD, Topley N: Peritoneal dialysis solution biocompatibility: inhibitory mechanisms and recent studies with bicarbonate-buffered solutions. Perit Dial Int 1997;17(suppl 2):S42-S46.
18. Sundaram S, Cendoroglo M, Cooker LA, Jaber BL, Faict D, Holmes CJ, et al: Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis 1997;30:680-689.
19. Topley N, Kaur D, Petersen MM, Jörres A, Williams JD, Faict D, et al: In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 1996;7:218-224.
20. Topley N, Kaur D, Petersen MM, Jörres A, Passlick Deetjen J, Coles GA, et al: Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 1996;49:1447-1456.
21. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729-739.
22. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434-2441.
23. Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, et al: Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003;23:381-390.
24. Mortier S, De Vriese AS, Van DV, Schaub TP, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002;13:480-489.
25. Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H, et al: Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004;24:48-57.
26. Ikehara O, Nishimura H, Naito T, Higuchi C, Sanaka T: Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on morphology of peritoneal membrane in rats. Nephron Exp Nephrol 2005;100:e30-e39.
27. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R, Williams JD, et al: In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis 2000;35:112-121.
28. Tranaeus A, The Bicarbonate/Lactate Study Group: A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. Perit Dial Int 2000;20:516-523.
29. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al: Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998;53:1061-1067.
30. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
31. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
32. Fusshoeller A, Plail M, Grabensee B, Plum J: Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004;19:2101-2106.
33. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, et al: Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003;14:2632-2638.
34. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al: Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
35. Schmitt CP, Von Heyl D, Haas S, Mehls O, Schaefer F, Mid European Pediatric PD Study Group (MEPPS): Peritoneal dialysis (PD) solution with reduced glucose degradation product (GDP) content lowers serum concentrations of advanced glycated endproducts (AGE) in children on automated PD (abstract). Nephrol Dial Transplant 2003;18(suppl 4):210-211.
36. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005;25:248-255.